Carcinoid, Neuroendocrine tumour (NET)
Results
Phase 3
This trial looked at telotristat etiprate (LX1606) for people who have symptoms of carcinoid syndrome.
Neuroendocrine tumours (NETs) are a rare group of cancers. These tumours make and release . They are normally found in the . The most common type that causes carcinoid syndrome are bowel ones.
This trial was open for people to join between April 2014 and April 2015. These results were published in 2018.
Recruitment start: 1 January 2013
Recruitment end: 31 March 2015
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Martyn Caplin
Experimental Cancer Medicine Centre (ECMC)
Lexicon Pharmaceuticals
Last reviewed: 22 Jun 2020
CRUK internal database number: 11546
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
